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Abstract
A total of 732 prospectively recruited German patients with metastatic renal cell carcinoma were classiﬁed as
either “trial-eligible” or “trial-ineligible” in accordance with the common exclusion criteria for clinical trials. The
“trial-ineligible” patients had shorter progression-free and overall survival compared with the “trial-eligible”
patients, whose outcomes were comparable with those from clinical trials. Physicians should be aware of
these differences when discussing the treatment options and outcome expectations with patients.
Introduction: Because “real-life” patients often do not meet the strict eligibility criteria of clinical trials, we assessed
the trial eligibility of patients with advanced or metastatic renal cell carcinoma (mRCC) in routine practice and
compared the survival of “trial-ineligible” and potentially “trial-eligible” patients. Patients and Methods: The present
prospective, multicenter German cohort study is recruiting patients from 110 oncology/urology outpatient centers and
hospitals at initiation of systemic ﬁrst-line treatment. The demographic, clinical, treatment, and survival data were
collected. We deﬁned patients as “trial-ineligible” when  1 exclusion criterion (Karnofsky performance status < 80%,
hemoglobin less than the lower limit of normal, noneclear cell carcinoma histology) was documented. Otherwise, the
patients were considered “trial-eligible”. Results: Of 732 patients included, 57% were classiﬁed as “trial-ineligible”.
Overall, the median ﬁrst-line progression-free survival (PFS) was 7.9 months (95% conﬁdence interval [CI], 6.9-8.9
months). The median ﬁrst-line PFS of “trial-eligible” and “trial-ineligible” patients was 11.0 months (95% CI, 9.6-13.1
months) and 5.3 months (95% CI, 4.6-6.5 months), respectively. The median OS of the “trial-eligible” and “trial-
ineligible” patients was 26.0 months (95% CI, 22.1-29.7 months) and 12.6 months (95% CI, 10.6-15.8 months),
respectively. Conclusion: Our data suggest that patients in routine practice differ from patients treated in clinical trials
and that almost 60% of mRCC patients in German routine practice would be ineligible for participation in clinical trials.
While their ﬁrst-line PFS and OS were shorter than those of “trial-eligible” patients, the PFS and OS of “trial-eligible”
patients were comparable with the results from clinical trials. Physicians should be aware of these differences when
discussing treatment options and outcome expectations with patients.
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Survival of Clinical Trial vs. Routine mRCC PatientsIntroduction and progression-free survival (PFS) of “trial-ineligible” patients with
Renal cell carcinoma (RCC) accounts for > 90% of renal ma-
lignancies, with clear cell carcinoma the most common subtype
(70%).1 Every year, RCC is diagnosed in approximately 15,500
patients in Germany and advanced or metastatic RCC (mRCC) is
diagnosed in about 40%.2 The development of novel agents tar-
geting signal transduction and angiogenesis pathways improved the
outcomes of patients with mRCC.3-6 Sorafenib and sunitinib were
the ﬁrst approved targeted agents for mRCC, followed by temsir-
olimus, everolimus, bevacizumab, pazopanib, axitinib,7 and, most
recently, nivolumab.8 The approval of these agents is based on re-
sults from controlled clinical registration trials with strict criteria for
trial eligibility to ensure high internal validity and patient popula-
tion homogeneity. However, the pertinent question is whether
mRCC patients in clinical trials are representative of the real-life
population for mRCC.9 Patients treated in routine practice often
do not meet the stringent criteria of clinical trials, especially those
patients with lower performance status and impairing comorbidities.
Hence, these patients are often classiﬁed as trial ineligible, and most
probably experience inferior outcomes. This was shown by a recent
study which reported that about one third of patients treated for
mRCC with ﬁrst-line vascular endothelial growth factor (VEGF)-
targeted therapy in 19 international cancer centers were classiﬁed as
“trial-ineligible” and had inferior outcomes.10
The German clinical registry on RCC (RCC Registry) gives in-
sights into the characteristics and treatments of patients with mRCC
receiving any systemic ﬁrst-line treatment in German routine
practice and permits investigations of their outcomes.
The objective of the present work was to assess the trial eligibility
of patients in routine care in Germany according to the presence of
common exclusion criteria and to compare the overall survival (OS)Figure 1 Cohort Deﬁnition. Database Cutoff for Outcome Data of Thi
as “Trial-Ineligible”, When at Least One of the Following
Performance Status <80%, Haemoglobin < Lower Limit of
These Three Exclusion Criteria Had Been Reported, Patien
nical Genitourinary Cancer Month 2016potentially “trial-eligible” patients.
Patients and Methods
Data Source
The study cohort was obtained from the RCC Registry, which
was started in December 2007. The RCC Registry is an ongoing,
prospective, open, longitudinal, multicenter cohort study conducted
by a network of > 280 ofﬁce- or hospital-based medical oncologists
and uro-oncologists located at 100 sites in Germany. A total of
1500 patients are intended to be recruited by the end of 2016.
Patients aged  18 years with histologically conﬁrmed mRCC will
be included if they have provided written informed consent not > 4
weeks after the start of any systemic ﬁrst-line treatment. For the ﬁrst
1000 patients, the maximum difference between the start of ﬁrst-
line treatment and enrollment was 1 year, to allow the analysis of
higher line treatment reality within the ﬁrst years of the project. For
the outcome analyses, the patients who provided written informed
consent > 6 weeks after the start of treatment were excluded to
avoid overestimation of the outcomes data (lead-time bias). Study
sites are encouraged to enroll patients consecutively to ensure un-
selected recruitment. The patients are treated according to physician
discretion.
At the time of enrollment, data on patient sociodemographic
data, tumor characteristics, clinical parameters, concomitant dis-
eases, and previous treatments are documented. Comorbidity is
collected using the Charlson comorbidity index.11 Additional
comorbidities can be recorded as free text. The presence of prog-
nostic factors according to the Memorial Sloan Kettering Cancer
Center (MSKCC)12 are documented at the start of each treatment
line, including low (<80%) Karnofsky performance status (KPS),s Patient Population Was May 15, 2015. Patients Were Classiﬁed
Main Exclusion Criteria Had Been Documented: Karnofsky
Normal, or Non-clear Cell Carcinoma Histology. When None of
ts Were Deﬁned as Potentially “Trial-Eligible”
Norbert Marschner et alelevated lactate dehydrogenase level (>1.5 times the upper limit of
normal), low hemoglobin (Hb) level (less than the lower limit of
normal), elevated corrected calcium (greater than upper limit
of normal), and the absence of previous nephrectomy. Using these
factors, the patient’s individual prognostic risk score is calculated
(low risk, 0 risk factor; intermediate risk, 1-2 risk factors; high risk,
3-5 risk factors). During therapy, all systemic antineoplastic treat-
ments (substance, dose, dose modiﬁcations, and duration) and
radiotherapy regimens and/or surgeries are documented.Table 1 Patient Characteristics and Treatment of Study Cohort
Parameter Total
Patients 732 (100)
Female sex 224 (30.6)
Median age (years)a 69.5
BMI (kg/m2)a 27.0  4.8
CCI (0-24)a,b 0.7  1.4
1 Comorbiditya 574 (78.4)
Nephrectomyc 542 (74.0)
Histologic typec
Clear cell carcinoma 523 (71.4)
Noneclear cell carcinoma 150 (20.5)
Unknown 59 (8.1)
KPS <80%a
Yes 156 (21.3)
No 532 (72.7)
Unknown 44 (6.0)
Hemoglobin <LLNa
Yes 298 (40.7)
No 418 (57.1)
Unknown 16 (2.2)
Calcium >ULNa
Yes 31 (4.2)
No 639 (87.3)
Unknown 62 (8.5)
LDH >1.5 times ULNa
Yes 83 (11.3)
No 564 (77.0)
Unknown 85 (11.6)
MSKCC risk categorya
Low risk (0) 234 (32.0)
Intermediate risk (1-2) 330 (45.1)
High risk (3-5) 64 (8.7)
Unknown 104 (14.2)
First-line treatment strategy
TKI 498 (68.0)
mTOR 112 (15.3)
Other 122 (16.7)
Data presented as n (%) or mean  standard deviation, unless noted otherwise.
Abbreviations: BMI ¼ body mass index; CCI ¼ Charlson comorbidity index; KPS ¼ Karnofski Perform
Sloan Kettering Cancer Center; mTOR ¼ mammalian target of rapamycin; TKI ¼ tyrosine kinase in
aAt the start of ﬁrst-line treatment.
bCharlson comorbidity index.11
cAt primary diagnosis.The treatment outcome parameters, including the dates of pro-
gression and date of death by any cause, are recorded. All data,
including data on mortality, are collected from the patients’ medical
ﬁles and transferred to a secure web-based electronic case report
form by physicians or trained study nurses. The data are updated
after any change in treatment or at least every 3 months. Patients are
followed up for a maximum of 3 years or until death, loss to follow-
up, or withdrawal of consent. Automated plausibility and
completeness checks with subsequently generated queries by theTrial Ineligible Potentially Trial Eligible
419 (57.2) 313 (42.8)
126 (30.1) 98 (31.3)
70.0 69.1
26.5  4.4 27.7  5.1
0.8  1.5 0.6  1.1
335 (80.0) 239 (76.4)
296 (70.6) 246 (78.6)
237 (56.6) 286 (91.4)
150 (35.8) 0 (0)
32 (7.6) 27 (8.6)
156 (37.2) 0 (0)
243 (58.0) 289 (92.3)
20 (4.8) 24 (7.7)
298 (71.1) 0 (0)
118 (28.2) 300 (95.8)
3 (0.7) 13 (4.2)
21 (5.0) 10 (3.2)
371 (88.5) 268 (85.6)
27 (6.4) 35 (11.2)
60 (14.3) 23 (7.3)
315 (75.2) 249 (79.6)
44 (10.5) 41 (13.1)
43 (10.3) 191 (61.0)
272 (64.9) 58 (18.5)
64 (15.3) 0 (0)
40 (9.5) 64 (20.4)
268 (64.0) 230 (73.5)
85 (20.3) 27 (8.6)
66 (15.8) 56 (17.9)
ance Status; LDH ¼ lactate dehydrogenase; LLN ¼ lower limit of normal; MSKCC ¼ Memorial
hibitor; ULN ¼ upper limit of normal.
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Table 2 Outcomes of Patients
Variable Total
Trial
Ineligible
Potentially
Trial Eligible P Value
First-line PFS <.0001
Patients 732 419 313
Events n (%) 519 (70.9) 312 (74.5) 207 (66.1)
Median (mo) 7.9 5.3 11.0
95% CI (mo) 6.9-8.9 4.6-6.5 9.6-13.1
Second-line PFS
Patients 378 199 179
Events n (%) 280 (74.1) 153 (76.9) 127 (70.9)
Median (mo) 4.3 4.0 4.9
95% CI (mo) 3.9-5.0 3.1-5.0 4.0-6.1
OS <.0001
Patients 732 419 313
Events n (%) 457 (62.4) 281 (67.1) 176 (56.2)
Median (mo) 18.0 12.6 26.0
95% CI (mo) 15.8-20.5 10.6-15.8 22.1-29.7
Abbreviations: CI ¼ conﬁdence interval; mo ¼ months; OS ¼ overall survival; PFS ¼
progression-free survival.
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4 - Clielectronic data capture system ensure data reliability. For quality
assurance reasons, the study sites are also contacted for correction or
completion of data, if necessary. Predeﬁned analyses are performed
annually. An ethics committee approved the study, which is regis-
tered at ClinicalTrials.gov (NCT00610012).
Cohort Deﬁnition
A total of 1142 patients with mRCC had been recruited by
114 study sites until May 15, 2014. For 1111 of these patients, the
baseline data and at least the start of ﬁrst-line treatment were
documented. Of these patients, 732 patients had provided written
informed consent no longer than 6 weeks after the beginning of
ﬁrst-line treatment and were included in the present analysis
(Figure 1). This restriction on patients starting treatment not long
before consent is crucial to avoid an overestimation of outcomes
data such as OS. The cutoff date for the outcome data of patients
included in the present analysis was May 15, 2015.
Deﬁnition of Trial Ineligibility and Eligibility
The trial eligibility and ineligibility of patients included in the
present analysis was deﬁned according to the common exclusion
criteria found in phase III clinical trials13-16 and explicitly captured by
the RCC Registry. Patients were classiﬁed as “trial-eligible” when 1
of the following criteria had been documented: KPS < 80%, Hb less
than the lower limit of normal, and/or noneclear cell carcinoma
histology. When none of these 3 criteria was fulﬁlled, patients were
deﬁned as potentially “trial-eligible”.
If patients had data missing for some of these criteria, they were
still classiﬁed as “trial-ineligible” if they had met  1 exclusion
criterion. If patients had data missing for  1 exclusion criterion but
were potentially eligible for all other criteria, they were considered
“trial-eligible” to provide the most conservative estimate of trial
eligibility.nical Genitourinary Cancer Month 2016Statistical Analysis
All analyses were performed using STATISTICA, version 10.0
(StatSoft, Inc), and SAS, version 9.4 (SAS Institute). The time to
events was analyzed using Kaplan-Meier estimates. First-line PFS was
deﬁned as the interval between the ﬁrst administration of any sys-
temic treatment and the date of progression or death before the start
of second-line treatment. Second-line PFS was deﬁned as the interval
between the beginning of systemic second-line treatment and the
date of progression or death before the start of third-line treatment.
OS was deﬁned as the interval from the start of ﬁrst-line treatment
until death from any cause. Patients without progression, alive, or lost
to follow-up were censored at the last contact or last documentation
date. The log-rank test was used to compare PFS and OS between
the “trial-ineligible” and “trial-eligible” patients. P values are reported
in an exploratory manner without adjustments for multiplicity.
Results
Patient Characteristics
The patient characteristics and treatment of the 732 patients
included in the present analysis are listed in Table 1. Of the 732
patients, 57% were classiﬁed as “trial-ineligible” and 43% as “trial-
eligible” (Figure 1). Approximately 70% of patients were male, and
the mean age was 68.0  10.0 years at the start of ﬁrst-line treat-
ment (Table 1). At the start of ﬁrst-line treatment in both patient
groups,  1 documented comorbidity was reported for about 80%
of patients.
Of the patients considered “trial-ineligible”, 7% had met all 3
exclusion criteria. Although 30% of the “trial-ineligible” patients
had met 2 exclusion criteria, most were “trial-ineligible” because of
1 criterion (63%; all data on ﬁle). The most common reason for
trial ineligibility was a lower Hb level (71%). The patients in the
“trial-ineligible” group had a poorer prognosis than that of the
“trial-eligible” patients according to the MSKCC risk score. Only
about 10% of “trial-ineligible” patients were classiﬁed as having low
risk at the start of ﬁrst-line treatment compared with approximately
60% of “trial-eligible” patients.
Systemic Treatment
The duration of ﬁrst-line treatment was shorter for the “trial-
ineligible” than for the “trial-eligible” patients. The corresponding
median treatment duration was 3.4 and 6.6 months. Overall, most
patients (68%) were treated with tyrosine kinase inhibitors (TKIs)
as ﬁrst-line treatment (Table 1). The “trial-eligible” patients received
TKIs slightly more often than did the “trial-ineligible” patients
(74% vs. 64%). The latter were treated more than twice as
frequently with mammalian target of rapamycin (mTOR) inhibitors
(20% vs. 9%; Table 1). About one half of all patients included in
the present analysis received second-line treatment.
Patient Outcomes
The median ﬁrst-line PFS of the “trial-eligible” patients was > 2
times longer than that of the “trial-ineligible” patients (11.0
months; 95% CI, 9.6-13.1 months; and 5.3 months; 95% CI, 4.6-
6.5 months, respectively; P < .0001; Table 2, Figure 2). The me-
dian PFS with second-line treatment did not differ between the 2
groups (“trial-ineligible”, 4.0 months; 95% CI, 3.1-5.0 months;
“trial-eligible”, 4.9 months; 95% CI, 4.0-6.1 months; Table 2).
Figure 2 Progression-Free Survival Since the Start of First-Line Treatment
Abbreviation: CI ¼ conﬁdence interval.
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and 56% of the “trial-eligible” patients had died. The median OS of
the “trial-eligible” patients was approximately 2 times longer than
that of the “trial-ineligible” patients (26.0 months; 95% CI, 22.1-
29.7 months; and 12.6 months, 95% CI, 10.6-15.8, respectively;
P < .0001; Table 2, Figure 3).
Similar results were obtained when patients treated with ﬁrst-line
mTOR inhibitors were excluded. The median OS for the “trial-
eligible” patients was 26.1 months (95% CI, 22.4-30.4 months)
and was 15.9 months (95% CI, 12.3-18.3 months) for the “trial-
ineligible” patients. The median PFS with ﬁrst-line treatment was
11.1 months (95% CI, 9.7-13.9 months) for “trial-eligible” patients
compared with 6.7 months (95% CI, 5.3-7.9 months) for “trial-
ineligible” patients. The median PFS with second-line treatment
was 4.9 months (95% CI, 4.0-6.1 months) for “trial-eligible” pa-
tients compared with 4.2 months (95% CI, 3.2-5.2 months) for the
“trial-ineligible” patients.
The median OS for the 150 “trial-ineligible” patients with
noneclear cell histology (11.4 months; 95% CI, 8.0-16.8
months) was slightly, but not signiﬁcantly, shorter than that for
the 237 “trial-ineligible” patients with clear cell histology (13.4
months; 95% CI, 10.6-17.9 months).
Discussion
Debate has ensued for some time regarding whether “real-life”
patients experience inferior OS and shorter treatment durations
compared with the results reported from clinical trials. Thedifferences were mostly explained by multiple reasons, including
higher comorbidity or worse performance status of the real-life
patients. The analyses of factors leading to trial participation (or
exclusion) could represent a reasonable method to explain the
substantial differences between the outcomes data derived from
randomized clinical trials and those reported from routine practice.
Our prospective real-life data suggest that almost 60% of mRCC
patients in German routine care would be ineligible for participation
in clinical trials, because they would meet common exclusion criteria
(KPS< 80%, Hb less than the lower limit of normal, and noneclear
cell carcinoma histology). As predicted, their ﬁrst-line PFS and OS
were signiﬁcantly inferior compared with those of the “trial-eligible”
patients. In contrast, patients without these factors had outcomes
comparable to the published data from clinical trials.
The results of the present study were limited by the observational
design. Because of possible differences other than the ones described
between the groups of patients compared (“trial-ineligible” and
“trial-eligible”), causal relations can not be drawn. Trial eligibility
and ineligibility were deﬁned using 3 exclusion criteria frequently
deﬁned in phase III clinical trials. The proportion of “trial-
ineligible” patients might have been underestimated, because
usually additional exclusion criteria are applied in clinical trials.
However, these could not be included in our deﬁnitions of trial
eligibility and ineligibility, mainly because they had not been
collected for all patients in the RCC Registry. Also, several patients
had missing data for some of the exclusion criteria; thus, our al-
gorithm to manage missing data and determine each patient’sClinical Genitourinary Cancer Month 2016 - 5
Figure 3 Overall Survival Since the Start of First-Line Treatment
Abbreviation: CI ¼ conﬁdence interval.
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of the number of “trial-ineligible” patients. Finally, in the RCC
Registry, a tumor assessment is not performed according to the
Response Evaluation Criteria In Solid Tumors, and the Registry
does not specify when, how often, or which criteria to use by
treating physician monitoring the disease course. Thus, the PFS data
we have presented should be considered as the best clinical
approximation and might not be identical to the PFS determined in
clinical trials.
A substantial number of patients classiﬁed as “trial-ineligible”
(35%) was also reported from 19 international cancer centers for
mRCC patients treated with ﬁrst-line VEGF therapy, with 65% of
patients deemed “trial-eligible”.10 This difference might have been
due to various reasons such as differing treatments, patient char-
acteristics, and deﬁnitions of trial eligibility and ineligibility. The
study by Heng et al10 was restricted to mRCC patients undergoing
VEGF-targeted therapy. In contrast, we included patients treated
with any type of systemic therapy, including patients with a poorer
prognosis receiving mTOR-targeted therapy. Differences were also
present in the sites of recruitment. The group of Heng et al10
recruited patients from international referral cancer centers world-
wide, but the RCC Registry recruits patients from oncology and
urology outpatient centers and (university) hospitals within the
German healthcare system. Also, the median age of our population
was about 10 years older than the age of those included in the study
by Heng et al,10 which might partially explain the greater propor-
tion of “trial-ineligible” patients in our analysis. Increasing age isnical Genitourinary Cancer Month 2016often associated with a lower KPS, one of the exclusion criteria
determining eligibility or the lack of eligibility. The difference in age
was also apparent between the entire population of the RCC Reg-
istry (median age, approximately 70 years) and the patients included
in large clinical trials, with a median age of 62,17 59,14 or 61 years.15
Our data showed that “trial-ineligible” patients had inferior
outcomes and poorer prognostic risk scores compared with the
“trial-eligible” patients. The median ﬁrst-line PFS and OS of the
“trial-ineligible” patients were 5.3 months and 12.6 months,
respectively, approximately 2 times lower than those of patients
potentially fulﬁlling trial eligibility. This effect was independent of
the type of ﬁrst-line treatment, with comparable results obtained
when the analyses were restricted to patients not receiving the
mTOR-targeted therapy usually prescribed to patients with poorer
prognosis.
Similar ﬁndings of inferior outcomes for “trial-ineligible” patients
were also reported for mRCC patients receiving ﬁrst-line VEGF-
targeted therapy.10 For the “trial-ineligible” and “trial-eligible” pa-
tients, the median ﬁrst-line PFS was 5.0 and 8.6 months and the
median OS was 12.5 and 28.4 months, respectively.10 These results
most likely represent a general observation of patients with malig-
nancies. In the Netherlands Cancer Registry, patients with stage IV
colorectal cancer not fulﬁlling the criteria for trial eligibility had
worse OS than that of eligible patients (9.3 vs. 15.7 months).18
In contrast to the study by Heng et al,10 which showed a shorter
median second-line PFS for “trial-ineligible” patients compared with
“trial-eligible” patients, in our analysis, the median PFS of
Norbert Marschner et alsecond-line treatment did not differ substantially between the “trial-
ineligible” and “trial-eligible” patients. This difference might have
resulted from differences in later line treatment with targeted agents.
All 3 factors used in our study to determine patient eligibility are
known prognostic factors for OS. A low KPS and the presence of
anemia are included in the MSKCC prognostic score12 and in the
prognostic score reported by Heng et al.19 In addition, it is known
that patients with noneclear cell carcinoma histology have inferior
survival compared with patients with clear cell histology.20 Thus,
the common exclusion criteria used in clinical trials are, in fact,
prognostic factors, and the patients excluded from trials are those
with an unfavorable prognosis. Our observation that patients with
these factors are very common in routine practice highlights that the
patient population treated in routine practice differs markedly from
the population selected for clinical trials. Outcome data from clin-
ical trials should therefore not be transferred to the entire patient
population but only to those patients fulﬁlling the inclusion criteria.
For the “trial-eligible” patients included in our analysis, the
median ﬁrst-line PFS of 11.0 months and median OS of 26.0
months were similar to the survival times reported in phase III
clinical trials, with a median ﬁrst-line PFS of 5.5 to 11.0
months14,17,21 and median OS of 17.8 to 26.4 months.13,15,17,22,23
Conclusion
Our data suggest that almost 60% of patients with mRCC in
German routine practice would be ineligible for participation in a
randomized clinical trial. Their ﬁrst-line PFS and OS were inferior
to those of “trial-eligible” routine patients, although those of “trial-
eligible” patients were comparable to those of clinical trial patients.
This ﬁnding highlights that the patient population selected for
clinical trials is not representative in terms of prognostic factors for
the general patient population treated in routine practice. Physicians
should be aware of these differences when discussing treatment
options, guideline adherence, and outcomes expectations with in-
dividual patients.
Clinical Practice Points
 We found that 57% of German mRCC patients would be
ineligible for participation in clinical trials.
 Their ﬁrst-line PFS and OS were shorter than those of “trial-
eligible” patients.
 The PFS and OS of the “trial-eligible” patients were comparable
with the clinical trial data.
 Thus, the outcome expectations should be adjusted for real-life
patients ineligible for clinical trials.Acknowledgments
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